Free Trial
→ Trump wipes out trillions overnight… (From Porter & Company) (Ad) Buy EWTX Stock  Free EWTX Stock Alerts

Edgewise Therapeutics (EWTX) Financials

Edgewise Therapeutics logo
$14.38 -2.17 (-13.09%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$14.09 -0.28 (-1.98%)
As of 05:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Edgewise Therapeutics

Annual Income Statements for Edgewise Therapeutics

This table shows Edgewise Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -17 -43 -68 -100 -134
Consolidated Net Income / (Loss)		 -17 -43 -68 -100 -134
Net Income / (Loss) Continuing Operations		 -17 -43 -68 -100 -134
Total Pre-Tax Income 		-17 -43 -68 -100 -134
Total Operating Income		 -17 -43 -72 -114 -159
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 43 72 114 159
Selling, General & Admin Expense		 2.21 11 18 23 32
Research & Development Expense		 15 32 54 91 127
Total Other Income / (Expense), net		 0.07 0.40 4.02 14 25
Interest & Investment Income		 0.07 0.40 4.02 14 25
Weighted Average Basic Shares Outstanding		 739.00K 37.53M 53.59M 63.72M 92.41M
Weighted Average Diluted Shares Outstanding		 739.00K 37.53M 53.59M 63.72M 92.41M
Weighted Average Basic & Diluted Shares Outstanding		 - 49.51M 63.26M 93.11M 95.21M

Quarterly Income Statements for Edgewise Therapeutics

This table shows Edgewise Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -17 -19 -23 -22 -26 -30 -29 -32 -32 -42
Consolidated Net Income / (Loss)		 -17 -19 -23 -21 -26 -30 -29 -31 -34 -40
Net Income / (Loss) Continuing Operations		 -17 -19 -23 -21 -26 -30 -29 -31 -34 -40
Total Pre-Tax Income 		-17 -19 -23 -21 -26 -30 -29 -31 -34 -40
Total Operating Income		 -18 -22 -26 -25 -29 -34 -35 -38 -40 -46
Total Operating Expenses		 18 22 26 25 29 34 35 38 40 46
Selling, General & Admin Expense		 4.37 5.47 5.83 5.78 5.67 6.18 7.06 7.43 8.21 9.17
Research & Development Expense		 14 17 20 20 24 28 28 31 32 36
Total Other Income / (Expense), net		 0.76 2.66 2.87 3.87 3.74 3.72 6.23 6.61 6.30 5.88
Interest & Investment Income		 0.76 2.66 2.87 3.87 3.74 3.72 6.23 6.61 6.30 5.88
Weighted Average Basic Shares Outstanding		 51.84M 53.59M 63.27M 63.38M 63.46M 63.72M 87.57M 93.52M 93.81M 92.41M
Weighted Average Diluted Shares Outstanding		 51.84M 53.59M 63.27M 63.38M 63.46M 63.72M 87.57M 93.52M 93.81M 92.41M
Weighted Average Basic & Diluted Shares Outstanding		 - 63.26M 63.28M 63.46M 63.46M 93.11M 93.40M 93.77M 94.69M 95.21M

Annual Cash Flow Statements for Edgewise Therapeutics

This table details how cash moves in and out of Edgewise Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 81 -89 6.43 64 -44
Net Cash From Operating Activities		 -15 -34 -53 -92 -109
Net Cash From Continuing Operating Activities		 -15 -34 -53 -92 -109
Net Income / (Loss) Continuing Operations		 -17 -43 -68 -100 -134
Consolidated Net Income / (Loss)		 -17 -43 -68 -100 -134
Depreciation Expense		 0.19 0.27 0.37 1.55 2.07
Amortization Expense		 - 0.00 -0.37 -9.34 -12
Non-Cash Adjustments To Reconcile Net Income		 0.35 4.40 11 18 25
Changes in Operating Assets and Liabilities, net		 1.95 4.63 4.09 -1.56 10
Net Cash From Investing Activities		 -24 -242 -71 103 -185
Net Cash From Continuing Investing Activities		 -24 -242 -71 103 -185
Purchase of Property, Plant & Equipment		 -0.20 -0.67 -5.55 -5.75 -1.31
Purchase of Investments		 -24 -288 -292 -256 -477
Sale and/or Maturity of Investments		 0.00 47 227 364 294
Net Cash From Financing Activities		 120 186 130 53 249
Net Cash From Continuing Financing Activities		 120 186 130 53 249
Repayment of Debt		 - 0.00 -0.25 -0.17 -0.26
Issuance of Common Equity		 0.00 186 129 53 240
Other Financing Activities, net		 0.20 0.11 0.41 0.12 9.48

Quarterly Cash Flow Statements for Edgewise Therapeutics

This table details how cash moves in and out of Edgewise Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 91 -88 26 -16 1.15 53 -56 13 1.32 -3.14
Net Cash From Operating Activities		 -12 -12 -23 -20 -22 -27 -29 -26 -27 -27
Net Cash From Continuing Operating Activities		 -12 -12 -23 -20 -22 -27 -29 -26 -27 -27
Net Income / (Loss) Continuing Operations		 -17 -19 -23 -21 -26 -30 -29 -31 -34 -40
Consolidated Net Income / (Loss)		 -17 -19 -23 -21 -26 -30 -29 -31 -34 -40
Depreciation Expense		 0.10 0.09 0.20 0.42 0.45 0.48 0.47 0.48 0.54 0.58
Amortization Expense		 0.19 -1.75 -2.03 -2.86 -2.33 -2.12 -3.10 -3.50 -3.18 -2.55
Non-Cash Adjustments To Reconcile Net Income		 3.17 3.74 3.84 4.01 4.57 5.14 4.71 5.39 6.37 8.25
Changes in Operating Assets and Liabilities, net		 2.07 5.49 -1.99 -0.34 0.96 -0.19 -2.16 3.03 3.03 6.43
Net Cash From Investing Activities		 -26 -76 49 3.44 23 27 -268 37 25 21
Net Cash From Continuing Investing Activities		 -26 -76 49 3.44 23 27 -268 37 25 21
Purchase of Property, Plant & Equipment		 -1.33 -3.29 -4.37 -0.76 -0.46 -0.16 -0.30 -0.22 0.31 -1.11
Purchase of Investments		 -68 -147 -17 -114 -85 -40 -328 -41 -45 -63
Sale and/or Maturity of Investments		 43 74 70 119 109 67 60 79 71 84
Net Cash From Financing Activities		 130 -0.30 0.02 0.37 -0.21 53 241 1.95 3.33 2.90
Net Cash From Continuing Financing Activities		 130 -0.30 0.02 0.37 -0.21 53 241 1.95 3.33 2.90
Issuance of Common Equity		 130 -0.41 0.00 0.34 - 53 239 0.42 - 0.47
Other Financing Activities, net		 0.05 0.03 0.02 0.03 0.00 0.06 1.93 1.58 3.55 2.43

Annual Balance Sheets for Edgewise Therapeutics

This table presents Edgewise Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 131 285 367 340 487
Total Current Assets		 130 284 357 327 475
Cash & Equivalents		 105 16 22 86 42
Short-Term Investments		 24 265 330 232 429
Prepaid Expenses		 0.55 2.98 5.05 8.60 5.31
Plant, Property, & Equipment, net		 0.52 0.91 8.53 10 9.50
Total Noncurrent Assets		 0.98 0.55 1.57 2.60 1.83
Other Noncurrent Operating Assets		 0.98 0.00 1.57 2.60 1.83
Total Liabilities & Shareholders' Equity		 131 285 367 340 487
Total Liabilities		 4.34 11 20 21 28
Total Current Liabilities		 4.34 11 17 17 24
Accounts Payable		 1.58 3.84 6.11 4.03 5.58
Accrued Expenses		 1.59 3.88 5.84 6.07 7.23
Current Employee Benefit Liabilities		 1.18 2.80 4.03 5.70 10
Other Current Liabilities		 - 0.00 0.61 0.98 1.00
Total Noncurrent Liabilities		 0.00 0.33 3.80 4.43 3.74
Other Noncurrent Operating Liabilities		 0.00 0.33 3.80 4.43 3.74
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -33 274 347 319 459
Total Preferred & Common Equity		 -33 274 347 319 459
Preferred Stock		 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -33 274 347 319 459
Common Stock		 0.73 352 493 563 837
Retained Earnings		 -34 -77 -145 -245 -379
Accumulated Other Comprehensive Income / (Loss)		 0.00 -0.51 -1.36 0.10 0.42

Quarterly Balance Sheets for Edgewise Therapeutics

This table presents Edgewise Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 346 331 311 554 532 511
Total Current Assets		 333 317 298 541 519 499
Cash & Equivalents		 48 32 33 30 43 45
Short-Term Investments		 280 278 257 502 468 448
Prepaid Expenses		 5.41 7.07 8.22 8.67 7.69 6.90
Plant, Property, & Equipment, net		 10 11 11 10 9.90 9.97
Total Noncurrent Assets		 2.64 2.77 2.76 2.20 2.31 1.88
Other Noncurrent Operating Assets		 2.64 2.77 2.76 2.20 2.31 1.88
Total Liabilities & Shareholders' Equity		 346 331 311 554 532 511
Total Liabilities		 18 19 21 19 21 22
Total Current Liabilities		 13 14 16 15 17 19
Accounts Payable		 3.88 3.78 5.32 4.72 6.80 5.65
Accrued Expenses		 5.97 6.62 5.68 5.97 5.14 6.13
Current Employee Benefit Liabilities		 2.07 3.13 4.41 2.92 4.24 6.19
Other Current Liabilities		 0.80 0.87 0.93 0.98 0.99 0.99
Total Noncurrent Liabilities		 4.85 4.77 4.60 4.27 4.00 3.45
Other Noncurrent Operating Liabilities		 4.85 4.77 4.60 4.27 4.00 3.45
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 329 311 290 535 510 489
Total Preferred & Common Equity		 329 311 290 535 510 489
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 329 311 290 535 510 489
Common Stock		 497 501 505 809 816 827
Retained Earnings		 -167 -189 -215 -273 -305 -339
Accumulated Other Comprehensive Income / (Loss)		 -0.25 -0.55 -0.42 -0.86 -1.05 1.05

Annual Metrics and Ratios for Edgewise Therapeutics

This table displays calculated financial ratios and metrics derived from Edgewise Therapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 0.00% -152.50% -66.88% -70.44% -38.43%
EBIT Growth		 0.00% -151.37% -65.82% -59.59% -38.89%
NOPAT Growth		 0.00% -151.37% -65.82% -59.59% -38.89%
Net Income Growth		 0.00% -150.03% -57.99% -48.08% -33.60%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 0.00% -128.97% -57.09% -74.69% -18.58%
Free Cash Flow Firm Growth		 0.00% 0.00% -102.70% -65.21% -16.42%
Invested Capital Growth		 0.00% -202.35% 24.78% 108.35% -2,606.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -30.72% 0.00% -10.65% -7.65%
EBIT Q/Q Growth		 0.00% -30.58% 0.00% -11.49% -7.94%
NOPAT Q/Q Growth		 0.00% -30.58% 0.00% -11.49% -7.94%
Net Income Q/Q Growth		 0.00% -17.43% 0.00% -12.00% -7.66%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% -16.64% 0.00% -19.45% -0.12%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -920.33% -18.18% -1.19%
Invested Capital Q/Q Growth		 0.00% -36.76% 0.00% -40.14% -199.37%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 99.60% 99.07% 94.39% 87.59% 84.25%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -13.50% -21.34% -21.78% -30.10% -34.40%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -19,615.08% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 3.56% -12.82% -21.78% -30.10% -34.40%
Return on Equity Simple (ROE_SIMPLE)		 51.24% -15.60% -19.51% -31.42% -29.14%
Net Operating Profit after Tax (NOPAT)		 -12 -30 -50 -80 -111
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.94% -6.12% -5.52% -6.00% -5.74%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -25.11% -24.21%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -17 -43 -72 -114 -159
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -17 -43 -72 -122 -169
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 2.75 1.28 2.18 5.51
Price to Tangible Book Value (P/TBV)		 0.00 2.75 1.28 2.18 5.51
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 860.13 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.02 -1.01 -1.01
Leverage Ratio		 1.03 1.04 1.05 1.06 1.06
Compound Leverage Factor		 1.03 1.03 0.99 0.93 0.90
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 126.36% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -26.36% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 24.67 41.93 13.02 18.62 53.91
Noncontrolling Interest Sharing Ratio		 126.36% 39.94% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 29.86 26.97 21.53 19.50 19.93
Quick Ratio		 29.73 26.69 21.22 18.98 19.71
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -26 -52 -86 -100
Operating Cash Flow to CapEx		 -7,208.87% -5,016.02% -949.06% -1,600.49% -8,310.06%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 -2.30 -6.95 -5.23 0.44 -11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 0.00 -4.65 1.72 5.67 -11
Enterprise Value (EV)		 207 472 93 376 2,058
Market Capitalization		 176 753 445 694 2,528
Book Value per Share		 ($45.22) $5.57 $6.47 $5.02 $4.85
Tangible Book Value per Share		 ($45.22) $5.57 $6.47 $5.02 $4.85
Total Capital		 127 274 347 319 459
Total Debt		 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00
Net Debt		 -129 -281 -352 -318 -470
Capital Expenditures (CapEx)		 0.20 0.67 5.55 5.75 1.31
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -3.79 -7.54 -12 -8.17 -19
Debt-free Net Working Capital (DFNWC)		 125 273 340 310 452
Net Working Capital (NWC)		 125 273 340 310 452
Net Nonoperating Expense (NNE)		 5.09 13 17 20 23
Net Nonoperating Obligations (NNO)		 -129 -281 -352 -318 -470
Total Depreciation and Amortization (D&A)		 0.19 0.27 -0.01 -7.79 -10
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 37.53M 53.59M 63.72M 92.41M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 37.53M 53.59M 63.72M 92.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 49.51M 63.26M 93.11M 95.21M
Normalized Net Operating Profit after Tax (NOPAT)		 -12 -30 -50 -80 -111
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.29% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Edgewise Therapeutics

This table displays calculated financial ratios and metrics derived from Edgewise Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -38.10% 0.00% -96.29% -74.43% -74.35% -49.53% -35.73% -48.08% -37.47% -33.84%
EBIT Growth		 -39.66% 0.00% -73.37% -53.65% -61.27% -53.37% -35.20% -50.39% -37.28% -34.49%
NOPAT Growth		 -39.66% 0.00% -73.37% -53.65% -61.27% -53.37% -35.20% -50.39% -37.28% -34.49%
Net Income Growth		 0.00% 0.00% -55.78% -33.62% -46.95% -55.26% -24.90% -46.71% -32.73% -31.58%
EPS Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -44.80% 0.00% -81.56% -24.56% -84.39% -126.32% -25.29% -28.99% -24.10% -0.47%
Free Cash Flow Firm Growth		 -339.22% -469.11% -190.73% -79.02% -19.46% -70.98% -5.19% -12.05% -12.03% 30.25%
Invested Capital Growth		 100.00% 24.78% 116.21% 174.85% 0.00% 108.35% 145.72% -183.63% -601.23% -2,606.64%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -12.86% -32.12% -15.99% -0.85% -12.81% -13.31% -5.29% -10.03% -4.73% -10.32%
EBIT Q/Q Growth		 -10.74% -20.90% -16.42% 1.42% -16.23% -14.97% -2.63% -9.65% -6.10% -12.63%
NOPAT Q/Q Growth		 -10.74% -20.90% -16.42% 1.42% -16.23% -14.97% -2.63% -9.65% -6.10% -12.63%
Net Income Q/Q Growth		 -8.91% -10.96% -17.63% 5.99% -19.77% -17.23% 5.37% -10.42% -8.36% -16.21%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 26.36% 0.90% -92.54% 11.36% -9.01% -21.63% -6.59% 8.74% -4.89% 1.52%
Free Cash Flow Firm Q/Q Growth		 -50.15% 3.86% -41.79% 12.54% -0.20% -37.59% 12.77% 6.83% -0.18% 14.33%
Invested Capital Q/Q Growth		 100.00% 0.00% 116.98% 71.96% -52.19% -40.14% 399.31% -158.52% -186.53% -199.37%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 95.82% 87.93% 88.85% 84.73% 87.30% 89.02% 82.08% 82.65% 84.41% 87.09%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -21.78% -25.74% -29.12% -61.59% -30.10% -24.51% -28.20% -31.90% -34.40%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -7,223.00% -4,422.78% -19,871.73% -19,615.08% -5,711.93% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -21.78% -25.74% -29.12% -61.59% -30.10% -24.51% -28.20% -31.90% -34.40%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -23.06% -26.08% -30.79% 0.00% -19.79% -22.70% -25.42% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -15 -18 -18 -21 -24 -24 -27 -28 -32
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.25% -1.25% -1.63% -1.34% -3.52% -1.92% -0.98% -1.17% -1.49% -1.97%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -7.43% - - - -6.94%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -18 -22 -26 -25 -29 -34 -35 -38 -40 -46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -24 -28 -28 -31 -36 -37 -41 -43 -48
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 1.28 1.28 1.57 1.25 2.18 2.16 3.30 5.12 5.51
Price to Tangible Book Value (P/TBV)		 0.00 1.28 1.28 1.57 1.25 2.18 2.16 3.30 5.12 5.51
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 105.87 118.20 101.27 860.13 286.33 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.02 -1.01 -1.00 -1.00 -1.01 -1.00 -1.00 -1.00 -1.01
Leverage Ratio		 1.03 1.05 1.05 1.05 1.07 1.06 1.04 1.05 1.06 1.06
Compound Leverage Factor		 0.99 0.92 0.93 0.89 0.94 0.95 0.86 0.87 0.89 0.93
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 13.47 14.61 15.39 10.23 19.40 37.06 47.76 66.96 54.67
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 21.53 26.22 22.01 18.23 19.50 37.08 30.24 26.35 19.93
Quick Ratio		 0.00 21.22 25.79 21.52 17.73 18.98 36.49 29.79 25.98 19.71
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -17 -24 -21 -21 -29 -26 -24 -24 -20
Operating Cash Flow to CapEx		 -899.47% -360.01% -522.57% -2,665.88% -4,826.70% -16,664.60% -9,628.96% -11,809.50% 0.00% -2,432.94%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -5.23 0.89 1.53 0.73 0.44 2.18 -1.28 -3.66 -11
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 5.09 1.72 6.37 3.57 0.73 5.67 1.29 -2.80 -4.39 -11
Enterprise Value (EV)		 490 93 94 180 74 376 625 1,170 2,010 2,058
Market Capitalization		 490 445 422 490 364 694 1,158 1,682 2,503 2,528
Book Value per Share		 $0.00 $6.47 $5.20 $4.92 $4.58 $5.02 $6.11 $5.47 $5.21 $4.85
Tangible Book Value per Share		 $0.00 $6.47 $5.20 $4.92 $4.58 $5.02 $6.11 $5.47 $5.21 $4.85
Total Capital		 0.00 347 329 311 290 319 535 510 489 459
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -352 -328 -310 -290 -318 -533 -512 -493 -470
Capital Expenditures (CapEx)		 1.33 3.29 4.37 0.76 0.46 0.16 0.30 0.22 -0.31 1.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -12 -7.30 -7.33 -8.11 -8.17 -5.93 -9.49 -12 -19
Debt-free Net Working Capital (DFNWC)		 0.00 340 321 303 282 310 527 502 480 452
Net Working Capital (NWC)		 0.00 340 321 303 282 310 527 502 480 452
Net Nonoperating Expense (NNE)		 4.71 3.96 4.85 3.73 5.10 6.44 4.20 4.82 5.83 7.78
Net Nonoperating Obligations (NNO)		 0.00 -352 -328 -310 -290 -318 -533 -512 -493 -470
Total Depreciation and Amortization (D&A)		 0.29 -1.66 -1.83 -2.43 -1.88 -1.64 -2.63 -3.02 -2.64 -1.97
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding		 0.00 53.59M 63.27M 63.38M 63.46M 63.72M 87.57M 93.52M 93.81M 92.41M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 53.59M 63.27M 63.38M 63.46M 63.72M 87.57M 93.52M 93.81M 92.41M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 63.26M 63.28M 63.46M 63.46M 93.11M 93.40M 93.77M 94.69M 95.21M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -15 -18 -18 -21 -24 -24 -27 -28 -32
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Edgewise Therapeutics' Financials

When does Edgewise Therapeutics's financial year end?

According to the most recent income statement we have on file, Edgewise Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Edgewise Therapeutics' net income changed over the last 4 years?

Edgewise Therapeutics' net income appears to be on an upward trend, with a most recent value of -$133.81 million in 2024, rising from -$17.12 million in 2020. The previous period was -$100.16 million in 2023. See where experts think Edgewise Therapeutics is headed by visiting Edgewise Therapeutics' forecast page.

What is Edgewise Therapeutics's operating income?
Edgewise Therapeutics's total operating income in 2024 was -$158.83 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $158.83 million
How has Edgewise Therapeutics revenue changed over the last 4 years?

Over the last 4 years, Edgewise Therapeutics' total revenue changed from $0.00 in 2020 to $0.00 in 2024, a change of 0.0%.

How much debt does Edgewise Therapeutics have?

Edgewise Therapeutics' total liabilities were at $27.60 million at the end of 2024, a 30.2% increase from 2023, and a 535.7% increase since 2020.

How much cash does Edgewise Therapeutics have?

In the past 4 years, Edgewise Therapeutics' cash and equivalents has ranged from $15.57 million in 2021 to $104.92 million in 2020, and is currently $41.67 million as of their latest financial filing in 2024.

How has Edgewise Therapeutics' book value per share changed over the last 4 years?

Over the last 4 years, Edgewise Therapeutics' book value per share changed from -45.22 in 2020 to 4.85 in 2024, a change of -110.7%.


Related Companies

This page (NASDAQ:EWTX) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...
Stansberry Research | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored